Phaseline

Companies › Dewpoint Therapeutics

Dewpoint Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DPTX3186
Wnt pathway inhibitor
–Phase 1Solid TumorsMay 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07312903DPTX3186Phase 1Solid TumorsOncologyMay 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.